Schedule 13G ownership disclosure
CytomX Therapeutics Inc
Common Stock, par value $0.00001 per share · CUSIP: 23284F105
Event date: 2025-06-30
- Filing-level shares
- 8,461,500.00
- Percent of class
- 5.4%
- OrbiMed Advisors LLC
Shares: 8,461,500.00 · Class: 5.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000782
- Form type
- SCHEDULE 13G
- Filer
- CytomX Therapeutics, Inc.
- CIK
- CIK 1501989
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership